--- title: "Skye Bioscience (SKYE) news: reverse split and class action" url: "https://aibio.space/companies/skye-bioscience/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "SKYE reverse split, class action, offering, Nasdaq notice and settlement news: Skye Bioscience files preliminary proxy for its Redx Pharma acquisition." --- SKYE Skye Bioscience, Inc. NASDAQ · United States # Skye Bioscience (SKYE) news SKYE reverse split, class action and offering news Legal · 2026-10-28 ## [Skye Bioscience faces nimacimab securities class action and two derivative suits](https://aibio.space/news/skye-bioscience-faces-nimacimab-securities-class-action-two-derivative/) Stout v. Skye Bioscience alleges misleading statements about nimacimab from November 4, 2024 to October 3, 2025. Two derivative suits captioned against Dhillon are stayed, and consolidation was sought on August 11. ## Latest Skye Bioscience news 1. 2026-10-28 Legal [Skye Bioscience faces October 2026 retrial of Cunning whistleblower suit](https://aibio.space/news/skye-bioscience-faces-october-2026-retrial-cunning-whistleblower-suit/) A jury found for former employee Wendy Cunning in 2023. The Ninth Circuit vacated the judgment in 2024. Skye now estimates the legal contingency at $5,417,250 and cites settlement talks. 2. 2026-10-26 Mergers [Skye Bioscience files preliminary proxy for its Redx Pharma acquisition](https://aibio.space/news/skye-bioscience-files-preliminary-proxy-redx-pharma-acquisition/) Redx holders would own about 59.74% of the combined company and Skye holders about 5.38%, at an assumed exchange ratio of 0.0892. Skye also plans a reverse stock split, and its proxy warns that stockholders will vote without certainty about the combined company's Nasdaq listing. 3. 2026-08-24 Financings [Skye Bioscience signs equity line with Redmile affiliate for up to $22,000,000](https://aibio.space/news/skye-bioscience-signs-equity-line-redmile-affiliate-up-22-000-000/) Skye Bioscience's equity line with a Redmile affiliate covers up to $22,000,000 and requires purchases of up to $2,000,000 a month once it starts. The line is reduced if the PIPE exceeds $103,000,000 and falls away at $125,000,000. 4. 2026-08-19 Listings [Skye Bioscience gets Nasdaq notice: stockholders' equity was ($497,307)](https://aibio.space/news/skye-bioscience-gets-nasdaq-notice-stockholders-equity-was-497-307/) Nasdaq said on August 18, 2026 that Skye Bioscience's stockholders' equity was a deficit of $497,307 at June 30, 2026, below the $2,500,000 minimum. The company has until October 2, 2026 to submit a plan to regain compliance. 5. 2026-08-14 Listings [Skye Bioscience outlines Redx Pharma deal in August 14, 2026 investor deck](https://aibio.space/news/skye-bioscience-outlines-redx-pharma-deal-august-14-2026-investor-deck/) Skye Bioscience's investor deck describes a U.K. scheme of arrangement to combine with Redx Pharma, a concurrent financing totaling $125 million, and a contingent value right for former Skye holders. The deck says Skye is discontinuing its CBeyond trial of nimacimab. 6. 2026-05-15 Listings [Skye Bioscience gets Nasdaq notice: stockholders' equity of $9,011,804 is below $10,000,000 minimum](https://aibio.space/news/skye-bioscience-gets-nasdaq-notice-stockholders-equity-9-011-804-below/) Nasdaq says Skye's stockholders' equity of $9,011,804, reported for the quarter ended March 31, 2026, is below the $10,000,000 Global Market minimum. The company has until June 29, 2026 to submit a plan. 7. 2026-03-19 Listings [Skye Bioscience gets Nasdaq bid price deficiency notice, has until September 14, 2026](https://aibio.space/news/skye-bioscience-gets-nasdaq-bid-price-deficiency-notice-has-until/) Nasdaq told Skye Bioscience (Nasdaq: SKYE) its stock closed below $1.00 for 30 consecutive business days. The company has 180 calendar days to regain compliance and says it will consider its options. ## Skye Bioscience at a glance - **Ticker**: SKYE - **Listing**: NASDAQ - **Country**: United States - **Cash, Jun 30, 2026**: $10.1 million ### Related companies - [Opus Genetics](https://aibio.space/companies/opus-genetics/) NASDAQ: IRD - [Reviva Pharmaceuticals Holdings](https://aibio.space/companies/reviva-pharmaceuticals/) OTC: RVPH - [Viking Therapeutics](https://aibio.space/companies/viking-therapeutics/) NASDAQ: VKTX - [Incyte](https://aibio.space/companies/incyte/) NASDAQ: INCY - [MabCure](https://aibio.space/companies/mabcure/) OTC: MBCI - [Veradermics](https://aibio.space/companies/veradermics/) NYSE: MANE - [Sonoma Pharmaceuticals](https://aibio.space/companies/sonoma-pharmaceuticals/) NASDAQ: SNOA - [Theriva Biologics](https://aibio.space/companies/theriva-biologics/) AMEX: TOVX ### Also on NASDAQ - [Genprex](https://aibio.space/companies/genprex/) GNPX - [Praxis Precision Medicines](https://aibio.space/companies/praxis-precision-medicines/) PRAX - [RAPID MICRO BIOSYSTEMS, INC.](https://aibio.space/companies/rapid-micro-biosystems/) RPID - [TELA Bio](https://aibio.space/companies/tela-bio/) TELA - [XORTX Therapeutics](https://aibio.space/companies/xortx-therapeutics/) XRTX - [ALX Oncology Holdings](https://aibio.space/companies/alx-oncology/) ALXO ## What Skye Bioscience does Skye Bioscience is a clinical-stage biotechnology company pioneering molecules that modulate G-protein-coupled receptors, or GPCRs, to treat obesity, overweight and metabolic disorders. Its lead candidate, nimacimab, is a humanized IgG4 peripherally restricted negative allosteric modulating antibody that targets the CB1 receptor and shows no cross-reactivity with CB2. Skye acquired nimacimab through its acquisition of Bird Rock Bio, Inc. in August 2023. The company's strategy includes advancing nimacimab as a combination therapy and as a standalone or second-line therapy, including in combination with incretin-based therapies. It also plans to explore additional metabolic indications where inflammation and fibrosis contribute to disease progression. The company cites a global obesity burden in which obesity affected more than 890 million adults as of 2022. It estimates a total addressable market of more than $100 billion annually by 2030. The text notes that the earlier CB1 inverse agonist rimonabant was taken off the market because of severe adverse neuropsychiatric side effects. | Product or program | What it is | Stage | |---|---|---| | Nimacimab | Peripherally restricted CB1 negative allosteric modulating antibody for obesity and overweight | in clinical development | Summarised from the company's [10-K filed Mar 10, 2026](https://www.sec.gov/Archives/edgar/data/1516551/000162828026016394/skye-20251231.htm). ## Skye Bioscience annual financials | Line | FY2025 | FY2024 | |---|---|---| | Net income (loss) | [-$55.9 million](https://www.sec.gov/Archives/edgar/data/1516551/000162828026016394/) | [-$26.6 million](https://www.sec.gov/Archives/edgar/data/1516551/000162828026016394/) | | Cash from operations | [-$43.1 million](https://www.sec.gov/Archives/edgar/data/1516551/000162828026016394/) | [-$25.2 million](https://www.sec.gov/Archives/edgar/data/1516551/000162828026016394/) | | Cash and equivalents | [$5.9 million](https://www.sec.gov/Archives/edgar/data/1516551/000162828026056968/) | [$68.4 million](https://www.sec.gov/Archives/edgar/data/1516551/000162828026016394/) | | Short-term investments | [$19.9 million](https://www.sec.gov/Archives/edgar/data/1516551/000162828026056968/) | [$0](https://www.sec.gov/Archives/edgar/data/1516551/000162828026016394/) | Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $8.1 million, plus short-term investments of $2.0 million, $10.1 million in all. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about Skye Bioscience Did Skye Bioscience do a reverse stock split? Our latest story on this, dated Oct 26, 2026: "Skye Bioscience files preliminary proxy for its Redx Pharma acquisition". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/skye-bioscience-files-preliminary-proxy-redx-pharma-acquisition/). Is there a class action against Skye Bioscience? Our latest story on this, dated Oct 28, 2026: "Skye Bioscience faces nimacimab securities class action and two derivative suits". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/skye-bioscience-faces-nimacimab-securities-class-action-two-derivative/). Has Skye Bioscience raised money recently? Our latest story on this, dated Aug 24, 2026: "Skye Bioscience signs equity line with Redmile affiliate for up to $22,000,000". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/skye-bioscience-signs-equity-line-redmile-affiliate-up-22-000-000/). Has Skye Bioscience received a Nasdaq deficiency notice? Our latest story on this, dated Aug 19, 2026: "Skye Bioscience gets Nasdaq notice: stockholders' equity was ($497,307)". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/skye-bioscience-gets-nasdaq-notice-stockholders-equity-was-497-307/). Has Skye Bioscience settled a lawsuit? Our latest story on this, dated Oct 28, 2026: "Skye Bioscience faces October 2026 retrial of Cunning whistleblower suit". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/skye-bioscience-faces-october-2026-retrial-cunning-whistleblower-suit/). What is the ticker symbol of Skye Bioscience? Skye Bioscience, Inc. trades under the ticker SKYE on NASDAQ. Where is Skye Bioscience listed? Skye Bioscience, Inc. is listed on NASDAQ. Our directory also records these other listings: LSX:A42JP2. What is the SEC CIK of Skye Bioscience? The SEC Central Index Key (CIK) for Skye Bioscience, Inc. is 1516551. Its filings are on SEC EDGAR. How many shares does Skye Bioscience have outstanding? 35,421,413 shares as of 2026-08-10, per the cover page of its 10-Q filed 2026-08-14. Which country or territory is Skye Bioscience listed under? Our directory records Skye Bioscience, Inc. under United States. What does Skye Bioscience do? Our directory classifies Skye Bioscience, Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline. What is the ISIN of Skye Bioscience? The ISIN recorded for Skye Bioscience, Inc. is US83086J3095. Does aibio.space cover Skye Bioscience? aibio.space lists Skye Bioscience, Inc. among 2,820 public biotech companies and publishes its news here as stories appear. Where is Skye Bioscience incorporated? SEC records list its state or country of incorporation as NV. What does Skye Bioscience develop? Skye Bioscience is a clinical-stage biotechnology company pioneering molecules that modulate G-protein-coupled receptors, or GPCRs, to treat obesity, overweight and metabolic disorders. Its lead candidate, nimacimab, is a humanized IgG4 peripherally restricted negative allosteric modulating antibody that targets the CB1 receptor and shows no cross-reactivity with CB2. ## Investor discussion: Skye Bioscience Members talk about Skye Bioscience (SKYE). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at Skye Bioscience, newest first. Each line links the filing it comes from. 1. 2026-10-26 Mergers Filed documents for a merger or acquisition. SEC Form PREM14A. [Source](https://www.sec.gov/Archives/edgar/data/1516551/000162828026067322/skye20261023-preliminarypr.htm) 2. 2026-09-11 Distress Reported the end of a material agreement. SEC Form 8-K (Items 1.02,5.02,8.01). [Source](https://www.sec.gov/Archives/edgar/data/1516551/000162828026061558/skye-20260908.htm) 3. 2026-08-24 Financings Reported a financing. SEC Form 8-K (Items 1.01,3.02,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1516551/000162828026058605/skye-20260821.htm) 4. 2026-08-19 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). [Source](https://www.sec.gov/Archives/edgar/data/1516551/000162828026057804/skye-20260818.htm) 5. 2026-08-14 Listings Reported a reverse stock split. SEC Form 8-K (Items 1.01,3.02,3.03,5.01,5.02,5.03,7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1516551/000162828026056966/skye-20260814xex992xdeck.htm) 6. 2026-08-14 Legal Disclosed a shareholder lawsuit, subpoena or other legal matter. SEC Form 10-Q. [Source](https://www.sec.gov/Archives/edgar/data/1516551/000162828026056968/skye-20260630.htm) 7. 2026-06-23 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01). [Source](https://www.sec.gov/Archives/edgar/data/1516551/000162828026044747/skye-20260618.htm) 8. 2026-05-29 Listings Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.03,5.07,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1516551/000162828026039233/skye-20260526.htm) 9. 2026-05-15 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). [Source](https://www.sec.gov/Archives/edgar/data/1516551/000162828026035535/skye-20260513.htm) 10. 2026-04-06 Mergers Filed documents for a merger or acquisition. SEC Form PREM14A. [Source](https://www.sec.gov/Archives/edgar/data/1516551/000162828026023908/skye_20260403xproxyxprelim.htm) 11. 2026-03-19 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). [Source](https://www.sec.gov/Archives/edgar/data/1516551/000162828026019878/skye-20260317.htm) 12. 2026-03-10 Distress Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-K. [Source](https://www.sec.gov/Archives/edgar/data/1516551/000162828026016394/skye-20251231.htm) 13. 2026-03-10 Legal Disclosed a shareholder lawsuit, subpoena or other legal matter. SEC Form 10-K. [Source](https://www.sec.gov/Archives/edgar/data/1516551/000162828026016394/skye-20251231.htm) 14. 2025-06-11 Legal Reported a change of independent auditor. SEC Form 8-K (Items 4.01,5.07,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1516551/000151655125000046/skye-20250606.htm) 15. 2025-03-20 Legal Disclosed a shareholder lawsuit, subpoena or other legal matter. SEC Form 10-K. [Source](https://www.sec.gov/Archives/edgar/data/1516551/000151655125000027/skye-20241231.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:SKYE on TradingView](https://www.tradingview.com/symbols/NASDAQ-SKYE/). ## SEC filings and registration - **SEC name**: Skye Bioscience, Inc. - **CIK**: 1516551 - **Industry (SIC)**: Pharmaceutical Preparations (2834) - **US tickers**: SKYE (Nasdaq) - **State or country of incorporation**: NV - **Fiscal year ends**: December 31 - **Filer category**: Non-accelerated filer
Smaller reporting company - **Business address**: 11250 EL CAMINO REAL, SUITE 100, SAN DIEGO, CA, 92130 - **Phone**: (858) 410-0266 - **Shares outstanding**: 35,421,413 as of 2026-08-10 (10-Q filed 2026-08-14) - **Former names**: Emerald Bioscience, Inc.; Nemus Bioscience, Inc.; LOAD GUARD LOGISTICS, INC. ### Recent filings (8-K and 6-K are the company's own announcements) - [8-K](https://www.sec.gov/Archives/edgar/data/1516551/000162828026061558/skye-20260908.htm) filed 2026-09-11 - [8-K](https://www.sec.gov/Archives/edgar/data/1516551/000162828026058605/skye-20260821.htm) filed 2026-08-24 - [8-K](https://www.sec.gov/Archives/edgar/data/1516551/000162828026057804/skye-20260818.htm) filed 2026-08-19 - [10-Q](https://www.sec.gov/Archives/edgar/data/1516551/000162828026056968/skye-20260630.htm) filed 2026-08-14 - [8-K](https://www.sec.gov/Archives/edgar/data/1516551/000162828026056966/skye-20260812.htm) filed 2026-08-14 - [8-K](https://www.sec.gov/Archives/edgar/data/1516551/000162828026044747/skye-20260618.htm) filed 2026-06-23 - [8-K](https://www.sec.gov/Archives/edgar/data/1516551/000162828026039233/skye-20260526.htm) filed 2026-05-29 - [8-K](https://www.sec.gov/Archives/edgar/data/1516551/000162828026035535/skye-20260513.htm) filed 2026-05-15 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001516551), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details Skye Bioscience, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker SKYE, recorded under United States. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: Skye Bioscience, Inc. - **Ticker**: SKYE - **Listing**: NASDAQ - **Country or territory**: United States - **Business scope**: Pharmaceuticals: Major - **ISIN**: US83086J3095 - **Other listed symbols**: LSX:A42JP2 - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-SKYE/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/skye-bioscience/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Skye Bioscience (SKYE) news: reverse split and class action", 2026-10-31, https://aibio.space/companies/skye-bioscience/